AstroNova Announces Financial Results for the First Quarter of Fiscal 2020
Reading Time: 6 minutes
Board of Directors Declares Regular Quarterly Cash Dividend of $0.07
Per Share
First-Quarter Fiscal 2020 Achievements (all comparisons with
first-quarter fiscal 2019)
- Bookings of $38.5 million, up 16%
- Revenue of $36.2 million, up 15%
- Operating income of $2.5 million, up 95%
- Earnings per diluted share of $0.23, up 92%
WEST WARWICK, R.I.–(BUSINESS WIRE)–AstroNova, Inc. (NASDAQ: ALOT), a global leader in data visualization
technologies, today announced financial results for the fiscal 2020
first quarter ended May 4, 2019.
CEO Commentary
“We executed well in the first quarter, generating strong year-over-year
gains in revenue, operating income and earnings per share,” said
President and CEO Greg Woods. “Our financial and operational performance
reflects the strategic investments we are making in new product
development, technology enhancements and geographic expansion, all
driven by our AstroNova Operating System (AOS). Through the AOS standard
set of tools and processes, we are realizing increased efficiencies,
enhancing operating leverage and driving growth to the bottom line.
“Both segments contributed to our positive results in Q1,” Woods said.
“In Product Identification, key business drivers included demand for our
new, five-color QL-300 tabletop printer, which allows commercial
printers and other customers to expand their capability to produce
high-quality, short-run specialty labels across a range of industries.
In the Test & Measurement segment, our results reflected solid momentum
in our key end markets.”
Business Outlook
“For fiscal 2020 we continue to expect modest revenue growth and
increased operating leverage for the full year as we expand the
application of the AstroNova Operating System across our business,”
Woods said. “However while so far we have been largely unaffected by the
grounding of the Boeing 737 MAX, we expect that the prolonged situation
may result in a slight impact on our second-quarter operating margin.
Whether or not this impact continues beyond the second quarter is
dependent on when the aircraft is returned to service.”
Operating Segment Results
Product Identification segment revenue in the first quarter of
fiscal 2020 was $23.6 million, an 18.2% increase compared with $20.0
million in the prior year, on higher sales of hardware, supplies and
services. Segment operating income was $2.9 million, or 12.2% of
revenue, versus $1.7 million, or 8.3% of revenue, in the prior year,
primarily reflecting higher revenue and improved operating leverage.
Test & Measurement segment revenue in the first quarter of
fiscal 2020 increased 9.2% to $12.6 million from $11.5 million in the
same period of fiscal 2019. Segment operating income was $2.6 million,
or 20.5% of revenue, for the first quarter of fiscal 2020 compared with
$2.3 million, or 19.6% of revenue, in the comparable period of fiscal
2019.
Financial Summary
Revenue in the first quarter totaled $36.2 million, an increase of 14.9%
from $31.5 million in the first quarter of fiscal 2019, reflecting
higher sales in both the Product Identification and Test & Measurement
segments.
Gross profit in the first quarter was $14.2 million, or 39.4% of
revenue, compared with $12.1 million, or 38.5% of revenue, for Q1 fiscal
2019. The increase in gross profit dollars and margin reflected higher
revenue in the 2020 period.
Operating expenses for the first quarter were $11.8 million compared
with $10.8 million in the same period of fiscal 2019.
Operating income for the first quarter was $2.5 million, or 6.8% of
revenue, compared with $1.3 million, or 4.0% of revenue, in the first
quarter of fiscal 2019.
Net income for the first quarter was $1.7 million, or $0.23 per diluted
share, versus $814,000, or $0.12 per diluted share, in the first quarter
of fiscal 2019.
First-quarter 2020 bookings increased 16% to $38.5 million from $33.3
million in the first quarter of 2019, with increases in both the Product
Identification and Test & Measurement segments.
Backlog at May 4, 2019 increased to a record $27.0 million, up 13% from
$23.9 million at the end of the fiscal 2019 first quarter.
Board Declares Quarterly Dividend
On June 4, 2019, the Company’s Board of Directors declared a regular
quarterly cash dividend of $0.07 per share. The dividend, which
represents a cash dividend of $0.28 per share on an annualized basis, is
payable on June 26, 2019, to shareholders of record on June 19, 2019.
First-Quarter Fiscal 2020 Conference Call
AstroNova will conduct an investor conference call at 9:00 a.m. ET
today. To participate on the conference call, please dial (877) 260-1479
(U.S. and Canada) or (334) 323-0522 (International) approximately 10
minutes prior to the start time and enter confirmation code 7303253
You can hear a replay of the conference call from 12:00 p.m. ET
Wednesday, June 5 until 12:00 p.m. ET Wednesday, June 12 by dialing
(888) 203-1112 (U.S. and Canada) or (719) 457-0820 (International). The
passcode is 7303253. A real-time and an archived audio webcast of the
call will be available through the “Investors” section of the AstroNova
website, https://investors.astronovainc.com.
About AstroNova
AstroNova, Inc. (NASDAQ: ALOT), a global leader in data visualization
technologies since 1969, designs, manufactures, distributes and services
a broad range of products that acquire, store, analyze and present data
in multiple formats. The Product Identification segment offers a variety
of hardware and software products and associated supplies that allow
customers to mark, track and enhance the appearance of their products.
The segment’s two business units are QuickLabel®, the industry leader in
tabletop digital color label printing and TrojanLabel®, an innovative
leader for professional label presses and specialty printers. The Test
and Measurement segment includes the Test & Measurement business unit,
which offers a suite of products and services that acquire, record and
analyze electronic signal data from local and networked sensors. The
segment also includes the AstroNova Aerospace business unit, which
designs and manufactures avionics equipment and systems that serve the
world’s aerospace and defense industries with proven advanced airborne
technology solutions for both the cockpit and the cabin. The key
products include flight deck printers, networking hardware and related
accessories. AstroNova is a member of the Russell Microcap® Index and
the LD Micro Index (INDEXNYSEGIS: LDMICRO). Additional information is
available by visiting www.astronovainc.com.
Forward-Looking Statements
Information included in this news release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not statements of
historical fact, but rather reflect our current expectations concerning
future events and results. These statements may include the use of the
words “believes,” “expects,” “intends,” “plans,” “anticipates,”
“likely,” “continues,” “may,” “will,” and similar expressions to
identify forward-looking statements. Such forward-looking statements,
including those concerning the Company’s anticipated performance in
fiscal 2020 and the effect of the grounding of the 737 MAX, involve
risks, uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or achievements
to be materially different from those expressed or implied by such
forward-looking statements. These risks, uncertainties and factors
include, but are not limited to, those factors set forth in the
Company’s Annual Report on Form 10-K for the fiscal year ended January
31, 2019 and subsequent filings AstroNova makes with the Securities and
Exchange Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. The reader is cautioned not
to unduly rely on such forward-looking statements when evaluating the
information presented in this news release.
| ASTRONOVA, INC. | ||||||||
| Condensed Consolidated Statements of Income | ||||||||
| In Thousands Except for Per Share Data | ||||||||
| (Unaudited) | ||||||||
|
Three Months Ended |
||||||||
| May 4, 2019 | April 28, 2018 | |||||||
| Net Revenue | $ | 36,181 | $ | 31,487 | ||||
| Cost of Revenue | 21,942 | 19,377 | ||||||
| Gross Profit | 14,239 | 12,110 | ||||||
| 39.4% | 38.5% | |||||||
| Operating Expenses: | ||||||||
| Selling & Marketing | 6,765 | 6,500 | ||||||
| Research & Development | 2,007 | 1,692 | ||||||
| General & Administrative | 2,999 | 2,653 | ||||||
| 11,771 | 10,845 | |||||||
| Operating Income | 2,468 | 1,265 | ||||||
| 6.8% | 4.0% | |||||||
| Other Income, Net | (368) | (270) | ||||||
| Income Before Taxes | 2,100 | 995 | ||||||
| Income Tax Provision | 400 | 181 | ||||||
| Net Income | $ | 1,700 | $ | 814 | ||||
| Net Income per Common Share – Basic | $ | 0.24 | $ | 0.12 | ||||
| Net Income per Common Share – Diluted | $ | 0.23 | $ | 0.12 | ||||
| Weighted Average Number of Common Shares – Basic | 6,971 | 6,788 | ||||||
| Weighted Average Number of Common Shares – Diluted | 7,248 | 6,916 | ||||||
| ASTRONOVA, INC. | ||||||||||
| Balance Sheet | ||||||||||
| In Thousands | ||||||||||
| (Unaudited) | ||||||||||
|
May 4, 2019 |
January 31, 2019 |
|||||||||
| ASSETS | ||||||||||
| CURRENT ASSETS | ||||||||||
| Cash and Cash Equivalents |
$ |
5,769 |
$ |
7,534 |
||||||
| Accounts Receivable, net | 21,970 | 23,486 | ||||||||
| Inventories, net | 32,043 | 30,161 | ||||||||
| Prepaid Expenses and Other Current Assets | 1,198 | 1,427 | ||||||||
| Total Current Assets | 60,980 | 62,608 | ||||||||
| PROPERTY, PLANT AND EQUIPMENT | 45,850 | 45,327 | ||||||||
| Less Accumulated Depreciation | (35,388) | (34,947) | ||||||||
| Property, Plant and Equipment, net | 10,462 | 10,380 | ||||||||
| OTHER ASSETS | ||||||||||
| Intangible Assets, net | 28,561 | 29,674 | ||||||||
| Goodwill | 12,136 | 12,329 | ||||||||
| Deferred Tax Assets | 2,927 | 2,928 | ||||||||
| Right of Use Asset | 1,826 | – | ||||||||
| Other Assets | 1,047 | 1,064 | ||||||||
| TOTAL ASSETS |
$ |
117,939 |
$ |
118,983 |
||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
| CURRENT LIABILITIES | ||||||||||
| Accounts Payable |
$ |
5,818 |
$ |
5,956 |
||||||
| Accrued Compensation | 2,767 | 5,023 | ||||||||
| Other Liabilities and Accrued Expenses | 2,848 | 2,911 | ||||||||
| Current Portion of Long-Term Debt | 4,932 | 5,208 | ||||||||
| Current Portion of Royalty Obligation | 2,000 | 1,875 | ||||||||
| Revolving Credit Facility | 1,500 | 1,500 | ||||||||
| Current Liability – Excess Royalty Payment Due | 1,301 | 1,265 | ||||||||
| Income Taxes Payable | 810 | 554 | ||||||||
| Deferred Revenue | 350 | 373 | ||||||||
| Total Current Liabilities | 22,326 | 24,665 | ||||||||
| NON CURRENT LIABILITIES | ||||||||||
| Long-Term Debt, net of current portion | 11,583 | 12,870 | ||||||||
| Royalty Obligation, net of current portion | 9,440 | 9,916 | ||||||||
| Lease Liability | 1,472 | – | ||||||||
| Deferred Tax Liabilities | 15 | 40 | ||||||||
|
Other Long-Term Liabilities |
1,489 | 1,717 | ||||||||
| TOTAL LIABILITIES | 46,325 | 49,208 | ||||||||
| SHAREHOLDERS’ EQUITY | ||||||||||
| Common Stock | 513 | 511 | ||||||||
| Additional Paid-in Capital | 54,474 | 53,568 | ||||||||
| Retained Earnings | 50,722 | 49,511 | ||||||||
| Treasury Stock | (33,077) | (32,997) | ||||||||
| Accumulated Other Comprehensive Loss, net of tax | (1,018) | (818) | ||||||||
| TOTAL SHAREHOLDERS’ EQUITY | 71,614 | 69,775 | ||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ |
117,939 |
$ |
118,983 |
||||||
| ASTRONOVA, INC. | |||||||||||||
| Revenue and Segment Operating Profit | |||||||||||||
| In Thousands | |||||||||||||
| (Unaudited) | |||||||||||||
| Three Months Ended | |||||||||||||
| Revenue | Segment Operating Profit | ||||||||||||
| May 4, 2019 | April 28, 2018 | May 4, 2019 | April 28, 2018 | ||||||||||
| Product Identification | $ | 23,591 | $ | 19,953 | $ | 2,886 | $ | 1,661 | |||||
| T&M | 12,590 | 11,534 | 2,581 | 2,257 | |||||||||
| Total | $ | 36,181 | $ | 31,487 | 5,467 | 3,918 | |||||||
| Corporate Expenses | 2,999 | 2,653 | |||||||||||
| Operating Income | 2,468 | 1,265 | |||||||||||
| Other Expense-Net | (368) | (270) | |||||||||||
| Income Before Income Taxes | 2,100 | 995 | |||||||||||
| Income Tax Provision | 400 | 181 | |||||||||||
| Net Income | $ | 1,700 | $ | 814 | |||||||||
Contacts
Scott Solomon
Senior Vice President
Sharon Merrill Associates
(617)
542-5300
[email protected]
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
